Closing Price: 66.3 cents (June 29)
Six-Month Stock Performance: -17.2%Received Nasdaq Notice: June 18 Management's Expected Action: Insmed has been given until Dec. 15 to get its stock trading above $1 again. The biopharmaceutical company said it is "considering appropriate business measures to address compliance with the continued listing standards." This isn't the first time Insmed has faced a possible delisting by the exchange. The company was in the same situation in 2008 before the Nasdaq suspended the bid price requirement due to the financial crisis. After the rule was reinstituted last year, Insmed was among the first to receive a notice letter in September 2009 before the shares climbed above $1 in March.